Ironwood’s stock drops 40% as short bowel syndrome drug shows mixed efficacy in PhIII
Ironwood Pharmaceuticals’ GLP-2 analog hit the primary endpoint in a registrational short bowel syndrome study, but fell short of key secondary outcomes in a slightly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
